KALA BIO
Development and commercialization of therapeutics using our proprietary nanoparticle-based Mucus Penetrating Particles.
Launch date
Employees
Market cap
€29.4m
Enterprise valuation
€14m (Public information from Sep 2024)
Share price
$5.8 KALA
Waltham Massachusetts (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 6.4m | 11.2m | 3.9m | - | 5.0m | - | 25.0m |
| % growth | 5 % | 77 % | (65 %) | - | - | - | - |
| EBITDA | (95.7m) | (107m) | (81.6m) | (35.6m) | - | - | - |
| % EBITDA margin | (1505 %) | (952 %) | (2097 %) | - | - | - | - |
| Profit | (104m) | (143m) | (44.8m) | (42.2m) | (44.4m) | (44.5m) | (18.7m) |
| % profit margin | (1640 %) | (1269 %) | (1152 %) | - | (888 %) | - | (75 %) |
| EV / revenue | 47.0x | 5.9x | -2.5x | - | 5.4x | - | -1.6x |
| EV / EBITDA | -3.1x | -0.6x | 0.1x | 0.9x | - | - | - |
| R&D budget | 18.4m | 11.5m | 17.7m | 18.6m | - | - | - |
| R&D % of revenue | 288 % | 102 % | 454 % | - | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$2.0m | Series A | ||
$3.0m | Early VC | ||
$7.2m | Growth Equity VC | ||
$11.5m | Series A | ||
$22.5m | Series B | ||
| N/A | $7.0m | Early VC | |
$68.0m | Series C | ||
| N/A | N/A | IPO | |
* | $110m | Post IPO Debt | |
* | N/A | $134m | Post IPO Equity |
* | $125m | Post IPO Debt | |
* | N/A | $31.0m | Post IPO Equity |
* | $12.5m | Post IPO Convertible | |
| Total Funding | €110m | ||
Related Content
Recent News about KALA BIO
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.